Skip to content

GLP-1 tool

Weigh-in tracker

Daily weight can swing 2 to 4 lb from water and salt alone, so a weekly trend line tells you far more than any single weigh-in.

Clinician review pending Updated

How to use it

  1. Step 1Set your start date and start weight.
  2. Step 2Pick a trial curve to compare with, or none.
  3. Step 3Log a weigh-in each week, at the same time of day.
  4. Step 4Export a CSV now and then as a backup.

Your data stays on this device

Entries are saved only in this browser's local storage. There's no account and nothing is sent to our servers. Clearing your browser data deletes them, so export a CSV from time to time.

How the comparison works

The dashed line applies the average trial result (for example 20.9% at 72 weeks for Zepbound 15 mg in SURMOUNT-1) to your start weight, using the same curve as the projection tool. It's a reference, not a target: in trials, people landed well above and below the average.

More glp-1 tools

GLP-1 weight-loss projection

Expected loss by drug, dose and week, from trial data

Open

GLP-1 dose schedule

Your titration calendar with calendar export

Open

Side-effect timeline

What the label reports at your dose step and week

Open

GLP-1 cost and savings

List, self-pay and savings-card prices side by side

Open

TDEE on a GLP-1

Your calorie needs vs what you actually eat now

Open

Tirzepatide dose calculator

Where you are on the Zepbound or Mounjaro ladder

Open

Common questions

How often should I weigh myself?

Once a week at the same time and in similar clothes works well. Daily weighing is fine if you watch the weekly average.

Is my weight data private?

Yes. It's stored only in your browser on this device and never sent to us.

Why did my weight go up this week?

Water, salt, constipation and hormones can add a few pounds short term. Look at the trend over 3 to 4 weeks.

Can I move my data to another phone?

Export a CSV on one device. There's no sync, because nothing is stored on a server.

Sources

  1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022
  2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021
  3. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). NEJM 2015

Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error